Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?

Abacavir Increases Purinergic P2X7 Receptor Activation by ATP: Does a Pro-inflammatory Synergism Underlie Its Cardiovascular Toxicity?

The cardiovascular toxicity of Abacavir is related to its purinergic structure. Purinergic P2X7-receptors (P2X7R), characterized by activation by high concentrations of ATP and with high plasticity, seem implicated. We appraise the nature of the interplay between Abacavir and P2X7R in generating vas...

Full description

Bibliographic Details
Main Authors:	Víctor Collado-Díaz, Maria Ángeles Martinez-Cuesta, Maria Amparo Blanch-Ruiz, Ainhoa Sánchez-López, Patricia García-Martínez, José E Peris, Iris Usach, Maria Dolores Ivorra, Alessandra Lacetera, Sonsoles Martín-Santamaría, Juan V. Esplugues, Angeles Alvarez
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Pharmacology
Subjects:	abacavir adenosine triphosphate P2X7 receptor leukocyte-endothelium interactions cardiovascular diseases allosteric modulator
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.613449/full

Similar Items

Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report
by: Mathew K. Koech, et al.
Published: (2022-11-01)

Interactions of Tenofovir, Lamivudine, Abacavir and Didanosine in Primary Human Cells
by: Saye H. Khoo, et al.
Published: (2011-06-01)

Abacavir use is associated with increased prothrombin conversion
by: Qiuting Yan, et al.
Published: (2023-04-01)

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy
by: Langdahl Bente L, et al.
Published: (2011-10-01)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Ho, Sharlene, et al.
Published: (2021)

Estimated use of abacavir among adults and children enrolled in public sector antiretroviral therapy programmes in Gauteng, South Africa
by: D Evans, et al.
Published: (2012-08-01)

Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
by: Wolf E, et al.
Published: (2010-04-01)

AOP-Based Transformation of Abacavir in Different Environments: Evolution Profile of Descyclopropyl-Abacavir and In Silico Toxicity Assessment of the Main Transformation Products
by: Eleni Evgenidou, et al.
Published: (2023-02-01)

Structural and Functional Basis for Understanding the Biological Significance of P2X7 Receptor
by: María Ángeles Martínez-Cuesta, et al.
Published: (2020-11-01)

Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults
by: Sharlene Ho, et al.
Published: (2020-05-01)

Bioequivalence study of abacavir/lamivudine (600/300-mg) tablets in healthy Thai volunteers under fasting conditions
by: Ekawan Yoosakul, et al.
Published: (2016-02-01)

Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing
by: Lucie Pražáková, et al.
Published: (2023-03-01)

Comparison of electrochemical and chemical approaches to forced oxidative degradation studies: Abacavir case study
by: Filip Vymyslický, et al.
Published: (2024-01-01)

The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection
by: A V Kravchenko, et al.
Published: (2014-11-01)

Enhanced Survival of High-Risk Medulloblastoma-Bearing Mice after Multimodal Treatment with Radiotherapy, Decitabine, and Abacavir
by: Marieke Gringmuth, et al.
Published: (2022-03-01)

Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS)
by: Z. C. Lim, et al.
Published: (2021-11-01)

Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire
by: Patricia T. Illing, et al.
Published: (2021-05-01)

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
by: Bagella P, et al.
Published: (2019-05-01)

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects
by: Eline Gall, et al.
Published: (2022-03-01)

Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study
by: Kunchok Dorjee, et al.
Published: (2017-10-01)

Abacavir versus Zidovudine-based regimens for treatment of HIV-infected children in resource limited settings: a retrospective cohort study
by: Teshale Ayele Mega, et al.
Published: (2020-03-01)

Unravelling the Proteomics of HLA-B*57:01<sup>+</sup> Antigen Presenting Cells during Abacavir Medication
by: Funmilola Josephine Haukamp, et al.
Published: (2022-01-01)

HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
by: Karam Mounzer, et al.
Published: (2019-01-01)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
by: Catherine Butkus Small, et al.
Published: (2017-04-01)

The Neutrophil Secretome as a Crucial Link between Inflammation and Thrombosis
by: María Amparo Blanch-Ruiz, et al.
Published: (2021-04-01)

Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics
by: Isabel Andújar, et al.
Published: (2022-09-01)

Rationalizing the use of PPIs: An unresolved matter
by: Julio Ponce, et al.
Published: (2013-03-01)

Purinergic Signaling in Spermatogenesis
by: Nadine Mundt, et al.
Published: (2022-04-01)

ANALYSIS OF MIXED COMBINATIONS OF MEDICINAL PRODUCTS BASED ON ABAKAVIR, LAMIVUDIN, ZIDOVUDIN USING THE METHOD OF MICROCOLONIES LIQUID CHROMATOGRAPHY
by: YU. A. GONCHIKOVA, et al.
Published: (2018-07-01)

M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative colitis.
by: Jesús Cosín-Roger, et al.
Published: (2013-01-01)

Role of Neutrophil Extracellular Traps in COVID-19 Progression: An Insight for Effective Treatment
by: María Amparo Blanch-Ruiz, et al.
Published: (2021-12-01)

Tenofovir-induced quadriparesis
by: Ashalatha Muppur, et al.
Published: (2020-01-01)

First-line HIV treatment: evaluation of backbone choice and its budget impact
by: Orietta Zaniolo, et al.
Published: (2013-03-01)

Erythrocytes Induce Endothelial Injury in Type 2 Diabetes Through Alteration of Vascular Purinergic Signaling
by: Ali Mahdi, et al.
Published: (2020-11-01)

Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model
by: Kayode Balogun, et al.
Published: (2022-05-01)

Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis
by: Lisanne E. N. Manson, et al.
Published: (2021-12-01)

HLA-B*5701 frequency in Chilean HIV-infected patients and in general population
by: Helena Poggi, et al.

¿Existe la filosofía de la técnica? Sobre ciencia, técnica, utopía y distopía
by: José Sanmartín Esplugues
Published: (2021-12-01)

¿Nuevos derroteros del Derecho internacional privado? El caso de la normativa estatal americana prohibiendo la aplicación del Derecho extranjero por sus tribunales y autoridades
by: Carlos Esplugues Mota
Published: (2015-05-01)

Procedimientos de insolvencia transfronterizos
by: Carlos Esplugues Mota
Published: (2006-07-01)